259 related articles for article (PubMed ID: 15199074)
41. Controversies in antimicrobial therapy: pitfalls in monitoring aminoglycoside therapy.
Fant WK
Am J Hosp Pharm; 1986 Mar; 43(3):641-6. PubMed ID: 3706319
[TBL] [Abstract][Full Text] [Related]
42. Back to the future: using aminoglycosides again and how to dose them optimally.
Drusano GL; Ambrose PG; Bhavnani SM; Bertino JS; Nafziger AN; Louie A
Clin Infect Dis; 2007 Sep; 45(6):753-60. PubMed ID: 17712761
[TBL] [Abstract][Full Text] [Related]
43. National survey of extended-interval aminoglycoside dosing.
Chuck SK; Raber SR; Rodvold KA; Areff D
Clin Infect Dis; 2000 Mar; 30(3):433-9. PubMed ID: 10722424
[TBL] [Abstract][Full Text] [Related]
44. Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.
Boyer A; Gruson D; Bouchet S; Clouzeau B; Hoang-Nam B; Vargas F; Gilles H; Molimard M; Rogues AM; Moore N
Drug Saf; 2013 Apr; 36(4):217-30. PubMed ID: 23508544
[TBL] [Abstract][Full Text] [Related]
45. Aminoglycosides use in patients over 75 years old.
Fraisse T; Gras Aygon C; Paccalin M; Vitrat V; De Wazieres B; Baudoux V; Lechiche C; Vicens A; Sotto A; Pagani L; Gaillat J; Forestier E; Gavazzi G
Age Ageing; 2014 Sep; 43(5):676-81. PubMed ID: 24590569
[TBL] [Abstract][Full Text] [Related]
46. Cost analysis of an aminoglycoside pharmacokinetic dosing program.
Schloemer JH; Zagozen JJ
Am J Hosp Pharm; 1984 Nov; 41(11):2347-51. PubMed ID: 6507436
[TBL] [Abstract][Full Text] [Related]
47. Evaluating new and traditional methods for aminoglycoside dosing in patients with various degrees of renal function.
Tsubaki T; Chandler MH
Pharmacotherapy; 1994; 14(3):330-6. PubMed ID: 7937274
[TBL] [Abstract][Full Text] [Related]
48. Aminoglycoside dosing: a randomized prospective study.
Kemme DJ; Daniel CI
South Med J; 1993 Jan; 86(1):46-51. PubMed ID: 8420016
[TBL] [Abstract][Full Text] [Related]
49. [Prediction of aminoglycoside nephrotoxicity].
Lucht F; Peyramond D; Robert D; Vincent P
Sem Hop; 1982 Sep; 58(35):2021-5. PubMed ID: 6293091
[TBL] [Abstract][Full Text] [Related]
50. [Aminoglygoside nephrotoxicity].
Baykal M
Mikrobiyol Bul; 1986 Jan; 20(1):32-6. PubMed ID: 3523171
[TBL] [Abstract][Full Text] [Related]
51. Aminoglycoside-induced vestibular injury: maintaining a sense of balance.
Ariano RE; Zelenitsky SA; Kassum DA
Ann Pharmacother; 2008 Sep; 42(9):1282-9. PubMed ID: 18648019
[TBL] [Abstract][Full Text] [Related]
52. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Duffaud F; Digue L; Tranchand B; Monjanel-Mouterde S; Guillet P; Nicoara A; Baciuchka M; Bagarry-Liegey D; Lacarelle B; Noble A; Durand A; Favre R
Ther Drug Monit; 2006 Apr; 28(2):212-8. PubMed ID: 16628133
[TBL] [Abstract][Full Text] [Related]
53. Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services.
Mathews A; Bailie GR
J Clin Pharm Ther; 1987 Oct; 12(5):273-91. PubMed ID: 3119606
[TBL] [Abstract][Full Text] [Related]
54. Aminoglycoside nephrotoxicity: keys to prevention.
Levin ML
J Crit Illn; 1994 Oct; 9(10):911-2, 915. PubMed ID: 10150695
[TBL] [Abstract][Full Text] [Related]
55. The relation between intermittent dosing and adherence: preliminary insights.
Kruk ME; Schwalbe N
Clin Ther; 2006 Dec; 28(12):1989-95. PubMed ID: 17296456
[TBL] [Abstract][Full Text] [Related]
56. Erectile response to vardenafil in men with a history of nonresponse to sildenafil: a time-from-dosing descriptive analysis.
Hatzichristou DG; Aliotta P; Auerbach S; Barkin J; Lording D; Murdock M; Wilkins HJ; McBride TA; Colopy MW; Carson CC;
Clin Ther; 2005 Sep; 27(9):1452-61. PubMed ID: 16291418
[TBL] [Abstract][Full Text] [Related]
57. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.
Rybak MJ; Abate BJ; Kang SL; Ruffing MJ; Lerner SA; Drusano GL
Antimicrob Agents Chemother; 1999 Jul; 43(7):1549-55. PubMed ID: 10390201
[TBL] [Abstract][Full Text] [Related]
58. Contrast media and nephropathy: findings from systematic analysis and Food and Drug Administration reports of adverse effects.
Solomon R; Dumouchel W
Invest Radiol; 2006 Aug; 41(8):651-60. PubMed ID: 16829749
[TBL] [Abstract][Full Text] [Related]
59. Aminoglycoside-induced nephrotoxicity--a focus on monitoring: a review of literature.
Destache CJ
J Pharm Pract; 2014 Dec; 27(6):562-6. PubMed ID: 25124375
[TBL] [Abstract][Full Text] [Related]
60. Prescriber adherence to pharmacokinetic monitoring service recommendations for aminoglycoside dosing and the risk of acute kidney injury.
Hennessy S; Leonard CE; Localio AR; Cohen A; Yang W; Cheung L; Strom BL; Herlim M; Feldman HI
Int J Clin Pharmacol Ther; 2011 Sep; 49(9):536-44. PubMed ID: 21888866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
